Last reviewed 2026-04-19 · How we verify

Lumentin® 44 Powder for oral foam

Lument AB · Phase 2 active Small molecule

Lumentin® 44 Powder for oral foam is a Small molecule drug developed by Lument AB. It is currently in Phase 2 development.

At a glance

Generic name	Lumentin® 44 Powder for oral foam
Sponsor	Lument AB
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Healthy Volunteer Trial Investigating MR-enterography Image Quality of Lumentin® 44 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lumentin® 44 Powder for oral foam CI brief — competitive landscape report
Lumentin® 44 Powder for oral foam updates RSS · CI watch RSS
Lument AB portfolio CI

Frequently asked questions about Lumentin® 44 Powder for oral foam

What is Lumentin® 44 Powder for oral foam?

Lumentin® 44 Powder for oral foam is a Small molecule drug developed by Lument AB.

Who makes Lumentin® 44 Powder for oral foam?

Lumentin® 44 Powder for oral foam is developed by Lument AB (see full Lument AB pipeline at /company/lument-ab).

What development phase is Lumentin® 44 Powder for oral foam in?

Lumentin® 44 Powder for oral foam is in Phase 2.

Manufacturer: Lument AB — full pipeline
Compare: Lumentin® 44 Powder for oral foam vs similar drugs
Pricing: Lumentin® 44 Powder for oral foam cost, discount & access